Skip to main content
Premium Trial:

Request an Annual Quote

Power3 Buys Rozetta-Cell

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Power3 Medical Products today announced a definitive agreement to acquire all the stock of stem cell firm Rozetta-Cell Life Sciences.

Upon completion of the deal, expected in October or November, Rozetta-Cell will be merged with Power3 and take its name.

Terms of the deal were not disclosed.

Rozetta-Cell focuses on the delivery and imaging of stem cells during therapy. In a statement, Ira Goldknopf, president and CEO of Power3, said that the acquisition will strengthen his firm's IP portfolio "in a major growth market by merging regenerative medicine with the technologies that we are using to identify disease-specific protein biomarkers and develop them into screening and diagnostic tests to address unmet medical needs."

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.